title: Liver transplantation for the management of hepatoblastoma.
abstract: BACKGROUND
  Hepatoblastoma (HEP) is the most frequent liver malignancy occurring in childhood. Surgical resection currently represents the gold standard for treatment. In patients with initially unresectable tumors, chemotherapy may induce remarkable reductions in size. In nonresponder patients, liver transplantation (OLTx) may offer a chance of cure.
  
  
  METHODS
  From 1990 to 2003, a total of 400 OLTx (31 pediatric transplants) have been performed at Padua University. Seven patients (4 males and 3 females) underwent OLTx for hepatoblastoma. All patients presented with bilobar liver involvement and had received chemotherapy according to the SIOPEL-1. In all patients preoperative staging was negative for extrahepatic involvement.
  
  
  RESULTS
  The mean age of the pts was 8.2 years (range 6.4 months to 34 years). Mean follow-up after OLTx was 41.4 months (median 36, range 3 to 108 months). Actuarial patient survival rates after OLTx for hepatoblastoma are 83.3%, 83.3%, and 56% at 1, 3, and 5 years, respectively. Five of seven subjects with HEP are alive after transplant at 3, 12, 36, 65, and 108 months. Two patients died owing to recurrent disease after 6 and 60 months, respectively, from transplantation. Another subject, primarily treated with surgical resection, shows HEP recurrence at 40 months after OLTx. The remaining 4 patients are alive and well at a mean follow-up of 28 months (median 24, range 3 to 65 months).
  
  
  CONCLUSIONS
  Liver transplantation may represent a valid therapeutic option for patients with unresectable HEP, but it is contraindicated in cases of recurrence following previous resection surgery. Neo-adjuvant chemotherapy is of paramount importance to obtain good long-term results.
authors.affiliation: Clinica Chirurgica 1 and Liver Transplantation Unit, P.G. Cevese Department of Surgical and Gastroenterological Sciences, Padua University, Via Giustiniani 2, Padua 35128, Italy.
authors.forename: U
authors.initials: U
authors.lastname: Cillo
authors.forename: F A
authors.initials: FA
authors.lastname: Ciarleglio
authors.forename: M
authors.initials: M
authors.lastname: Bassanello
authors.forename: A
authors.initials: A
authors.lastname: Brolese
authors.forename: A
authors.initials: A
authors.lastname: Vitale
authors.forename: P
authors.initials: P
authors.lastname: Boccagni
authors.forename: G
authors.initials: G
authors.lastname: Zanus
authors.forename: L
authors.initials: L
authors.lastname: Zancan
authors.forename: L
authors.initials: L
authors.lastname: D'Antiga
authors.forename: P
authors.initials: P
authors.lastname: Dall'igna
authors.forename: U
authors.initials: U
authors.lastname: Montin
authors.forename: E
authors.initials: E
authors.lastname: Gringeri
authors.forename: A
authors.initials: A
authors.lastname: Carraro
authors.forename: G
authors.initials: G
authors.lastname: Cappuzzo
authors.forename: P
authors.initials: P
authors.lastname: Violi
authors.forename: M
authors.initials: M
authors.lastname: Baldessin
authors.forename: A
authors.initials: A
authors.lastname: Bridda
authors.forename: D F
authors.initials: DF
authors.lastname: D'Amico
authors.forename: G
authors.initials: G
authors.lastname: Perilongo
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D018197:Hepatoblastoma / Q000601:surgery*; D006801:Humans; D007223:Infant; D008113:Liver Neoplasms / Q000601:surgery*; D016031:Liver Transplantation / Q000401:mortality / Q000706:statistics & numerical data*; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome